Hennion & Walsh Asset Management Inc. Reduces Position in Grifols, S.A. (NASDAQ:GRFS)

Hennion & Walsh Asset Management Inc. reduced its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 9.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 221,187 shares of the biotechnology company’s stock after selling 22,964 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $1,646,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GRFS. Brandes Investment Partners LP lifted its position in Grifols by 8.7% during the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after acquiring an additional 1,481,924 shares during the period. Armistice Capital LLC raised its stake in shares of Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after purchasing an additional 1,244,000 shares during the last quarter. Whitebox Advisors LLC lifted its holdings in shares of Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock worth $37,487,000 after purchasing an additional 1,519,093 shares during the period. Sei Investments Co. boosted its position in Grifols by 4.7% in the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after buying an additional 100,131 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Grifols by 144.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after buying an additional 1,181,959 shares during the period.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

NASDAQ:GRFS opened at $7.27 on Friday. The firm’s fifty day moving average is $7.86 and its two-hundred day moving average is $8.19. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of 6.01 and a beta of 0.41. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a one year low of $5.30 and a one year high of $9.96.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.